Astellas Beats Generics' Bid To Nix Cancer Drug Patent
Generic-drug makers on Wednesday failed to convince a London appellate judge to nix remaining protections for Astellas Pharma's blockbuster prostate cancer treatment Xtandi because the evidence provided was "tainted with hindsight."...To view the full article, register now.
Already a subscriber? Click here to view full article